• Citer

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

par Wells, Athol U;Flaherty, Kevin R;Brown, Keith;Inoue, Yoshikazu;Devaraj, Anand;Richeldi, Luca;Moua, Teng;Crestani, Bruno;Wuyts, Wim;Stowasser, Susanne;Quaresma, Manuel;Goeldner, Rainer Georg;Schlenker-Herceg, Rozsa;Bondue, Benjamin ;INBUILD trial investigators, Martin;Kolb,
Référence The Lancet. Respiratory medicine, 8, 5, page (453-460)
Publication Publié, 2020-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Auteur:	Wells, Athol U; Flaherty, Kevin R; Brown, Keith; Inoue, Yoshikazu; Devaraj, Anand; Richeldi, Luca; Moua, Teng; Crestani, Bruno; Wuyts, Wim; Stowasser, Susanne; Quaresma, Manuel; Goeldner, Rainer Georg; Schlenker-Herceg, Rozsa; Bondue, Benjamin; INBUILD trial investigators, Martin; Kolb,
Informations sur la publication:	The Lancet. Respiratory medicine, 8, 5, page (453-460)
Statut de publication:	Publié, 2020-05-01
Sujet CREF:	Sciences bio-médicales et agricoles
Langue:	Anglais
Identificateurs:	urn:issn:2213-2600
	info:doi/10.1016/S2213-2600(20)30036-9
	info:pii/S2213-2600(20)30036-9
	info:pmid/32145830